Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy Failure

Inclusion Criteria: * 1\. The patient understood, participated voluntarily and signed the informed consent 2\. Age 18-65 3\. Cytologically or histologically confirmed malignancy 4\. Complete clinical data 5\. The number of primary and regional metastatic lymph nodes and distant metastatic lesions was ≤10, and the number of organ metastases was ≤5. 6\. Patients with malignant tumors who are resistant to immunotherapy (the patient's disease progression is evaluated after 6-8 weeks of treatment without improvement of clinical symptoms), and no standard treatment options are available. 7\. Measurable primary lesions and regions Exclusion Criteria: * 1\. Missing key patient data 2\. Refusing or not cooperating with the study 3\. Patients who have participated in other clinical studies/trials within 3 months 4\. Patients with brain metastases 5\. Patients with any conditions that the investigator judged to be ineligible for study participation 6\. Patients with uncontrolled severe medical diseases who cannot tolerate radiotherapy 7\. Past immune-related side effects (immune myocarditis, pneumonia, etc.) 8\. Previous history of radiation therapy